fosaprepitant: Clinical Trials

13 trials of fosaprepitant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 recruiting, 2 terminated, 1 unknown. 13 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Completed 8, Recruiting 2, Terminated 2, Unknown 1
Phase 21Recruiting 1

Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Fosaprepitant, Tropisetron, Olanzapine - Multiple Myeloma
Phase 3RecruitingThe Affiliated People's Hospital of Ningbo University922025-10-312026-02-17
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
QLM2010 for injection;dexamethasone, fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone - Chemotherapy-Induced Nausea and Vomiting
Phase 3CompletedQilu Pharmaceutical Co., Ltd.6652025-01-032025-11-18
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea
Phase 2 / Phase 3RecruitingMontefiore Medical Center2002024-11-132026-05-18
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
HR20013 for injection;dexamethasone, fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone - Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Phase 3CompletedFujian Shengdi Pharmaceutical Co., Ltd.7542022-09-212023-10-27
Anti-emetic Prophylaxis With or Without Dexamethasone
Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen - Chemotherapy-induced Nausea and Vomiting
Phase 3CompletedHenan Cancer Hospital4422022-02-012024-10-10
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Fosaprepitant, tropisetron, Dexamethasone - Cervical Cancer, Nasopharyngeal Cancer
Phase 3CompletedShantou University Medical College1162021-07-012024-02-06
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Granisetron transdermal patch, Palonosetron, Aprepitant - Chemotherapy-induced Nausea and Vomiting (CINV)
Phase 3UnknownFudan University1402021-06-102021-06-03
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA) - Gynecologic Cancer
Phase 3TerminatedUniversity of Michigan Rogel Cancer Center622020-12-282025-06-18
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone - Malignant Neoplasm
Phase 3CompletedAlliance for Clinical Trials in Oncology6902018-11-202025-04-06
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
Fosaprepitant, Placebo for fosaprepitant, Ondansetron - Chemotherapy-induced Nausea and Vomiting
Phase 3TerminatedMerck Sharp & Dohme LLC752015-09-142019-03-15
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
APF530, Ondansetron, Ondansetron placebo - Chemotherapy-induced Nausea and Vomiting
Phase 3CompletedHeron Therapeutics9422014-03-012026-03-02
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Fosaprepitant dimeglumine, Fosaprepitant Placebo, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3CompletedMerck Sharp & Dohme LLC10152012-09-242018-09-04
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Fosaprepitant dimeglumine, Placebo - Nausea, Vomiting
Phase 3CompletedOdense University Hospital2462010-04-012015-04-24

Conditions studied

Vomiting (9)  ·  Nausea (3)  ·  Genital Neoplasms, Female (1)  ·  Multiple Myeloma (1)  ·  Nasopharyngeal Neoplasms (1)  ·  Neoplasms (1)  ·  Signs and Symptoms, Digestive (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Fudan University (1)  ·  Fujian Shengdi Pharmaceutical Co., Ltd. (1)  ·  Henan Cancer Hospital (1)  ·  Heron Therapeutics (1)  ·  Montefiore Medical Center (1)  ·  Odense University Hospital (1)  ·  Qilu Pharmaceutical Co., Ltd. (1)  ·  Shantou University Medical College (1)  ·  The Affiliated People's Hospital of Ningbo University (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

China (5)  ·  United States (4)  ·  Australia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Guam (1)  ·  Norway (1)

Top investigators

Aimee Rolston (1)  ·  Benjamin W Friedman, MD MS (1)  ·  Christina Ruhlmann, MD (1)  ·  Chuangzhen Chen (1)  ·  Dorothy Keefe, MD, FRACP (1)  ·  Felix Hilpert, MD, DMSci (1)  ·  Gunnar Kristensen, MD, PhD (1)  ·  Henrik Roed, MD, DMSci (1)  ·  Jacob C Lindegaard, MD (1)  ·  Jorn Herrstedt, MD, DMSci (1)  ·  Mark Gelder, MD (1)  ·  Peipei Ye (1)  ·  Petra Feyer, MD, DMSci (1)  ·  Rudolph Navari, MD, PhD, FACP (1)

Results publications

PMID 26449391, PMID 26952945, PMID 26997579, PMID 29808377, PMID 32988373, PMID 37284847, PMID 37851143, PMID 39621965, PMID 41520166

NIH funding

2009 (1), 2014 (1), UG1CA189823 (1)